Protein Kinase Inhibitors: all 15,278 studies that test it
Page 109 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingNCT03040973Phase 2
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
- Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2
- Apatinib and Chemotherapy Sequential Treatment With Cervical CancerStatus unknownNCT03029013Not applicable
- WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck CancerCompletedNCT03028766Phase 1
- A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompletedNCT03027284Phase 1
- A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
- A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma MultiformeStatus unknownNCT03025893Phase 2/3
- Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaActive, not recruitingNCT03024489Phase 1/2
- Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCompletedNCT03023319Phase 1
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1
- Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
- A Phase I Study of TQ-B3101 on Tolerance and PharmacokineticsStatus unknownNCT03019276Phase 1
- Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory CancersCompletedNCT03017833Phase 1
- K-BASKET, TAS-117, PI3K/AKT Gene AberrationCompletedNCT03017521Phase 2
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyStatus unknownNCT03016715Phase 2
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionTerminatedNCT03014297Phase 1
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
- Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryCompletedNCT03009201Phase 1
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT03008408Phase 2
- Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLCStatus unknownNCT03008109Phase 3
- The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric CancerStatus unknownNCT03007446Phase 2
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03007147Phase 3
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1
- A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
- ML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWithdrawnNCT03005639Phase 2
- Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2
- Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
- Therapeutic Effect of Ursodeoxycholic Acid in Functional DyspepsiaActive, not recruitingNCT03004118Phase 4
- MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03004105Phase 2
- EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT03002844Phase 2
- Study of Tofacitinib in Refractory DermatomyositisCompletedNCT03002649Phase 1
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLCCompletedNCT03001609Phase 1
- Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver ProblemsStatus unknownNCT03000218Phase 1
- Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate CancerCompletedNCT02998242Not applicable
- Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
- Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)Status unknownNCT02995187Phase 2
- Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTCTerminatedNCT02992340Phase 1/2
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant RecipientsWithdrawnNCT02990312Phase 4
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnNCT02989870Phase 1
- Apatinib for Advanced Non-squamous Head and Neck CancerStatus unknownNCT02989259Phase 2
- G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownNCT02983071Phase 1/2
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerStatus unknownNCT02980809Phase 2
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedNCT02979821Phase 2
- Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade GliomasCompletedNCT02978261Phase 1
- A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid TumoursStatus unknownNCT02977364Phase 1
- Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentCompletedNCT02976896Phase 2
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02976116Phase 2
- Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT02975141Phase 1
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung CancerTerminatedNCT02973763Phase 1
- A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerStatus unknownNCT02973737Phase 3
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLLTerminatedNCT02973399Phase 1
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy SubjectsCompletedNCT02972905Phase 1
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.CompletedNCT02971696Phase 3
- Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical StudyCompletedNCT02970630Phase 2
- Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseCompletedNCT02970019Phase 1
- TB Host Directed TherapyStatus unknownNCT02968927Phase 2
- Phase I Study of SHR7390 in Patients With Advanced Solid TumorsStatus unknownNCT02968485Phase 1
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
- Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA TreatmentCompletedNCT02967250Phase 1
- Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaCompletedNCT02966821Phase 2
- Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial ChemoimmunotherapyTerminatedNCT02966730Early Phase 1
- A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedNCT02966171Phase 1
- A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
- Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.CompletedNCT02964689Phase 1
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentActive, not recruitingNCT02962414Phase 3
- Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's MacroglobulinemiaCompletedNCT02962401Phase 2
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3
- Study of ASN003 in Subjects With Advanced Solid TumorsTerminatedNCT02961283Phase 1
- Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationStatus unknownNCT02961270Phase 2
- Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedNCT02960945Phase 1
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLCStatus unknownNCT02960607Phase 2
- Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerCompletedNCT02959749Phase 2/3
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
- Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
- Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled TrialStatus unknownNCT02951637Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2
- A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
- Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.CompletedNCT02945852Phase 2
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck CancerStatus unknownNCT02943252Phase 2
- Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic CarcinomaStatus unknownNCT02942693Phase 2
- Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02942355Phase 2
- Study of Ixazomib and Erlotinib in Solid TumorsCompletedNCT02942095Phase 1